A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Fenofibric Acid

Peroxisome Proliferator Receptor alpha Agonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2013-12-04
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.153/unit
13 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.198
Across all dosage forms in distribution.
Highest NADAC
$0.237
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Fenofibric Acid used for?

Fenofibric Acid is a Peroxisome Proliferator Receptor alpha Agonist medication tracked in Medicare Part D.

Is there a generic for Fenofibric Acid?

No. Fenofibric Acid is brand-only with no generic equivalents currently in market.

How much does my plan pay for Fenofibric Acid?

Across 329 Part D plans, Fenofibric Acid averages $0.198/unit (NADAC). Lowest available: $0.153/unit. Highest in distribution: $0.237/unit.

Is Fenofibric Acid on the FDA shortage list?

No. Fenofibric Acid is not currently on the FDA Drug Shortage Database.

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Peroxisome Proliferator Receptor alpha Agonist3 alternatives in D1
01
Fenofibrate
Brand: ANTARA
$0.079Lowest NADAC
26Generic mfrs
$89.1MCY24 Part D spend
Compare →
02
Gemfibrozil
Brand: Lopid
$0.103Lowest NADAC
8Generic mfrs
$21.1MCY24 Part D spend
Compare →
03
Pioglitazone
Brand: Actos
$0.069Lowest NADAC
11Generic mfrs
$65.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (13 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.